Zentalis Pharmaceuticals (ZNTL) has announced that the FDA has lifted the partial clinical hold on studies of azenosertib, their selective and orally bioavailable inhibitor of WEE. This clearance allows the company to continue enrollment in all ongoing azenosertib clinical studies without any alterations to the clinical development plan.
Zentalis plans to collaborate with clinical trial investigators to restart study activities across the azenosertib development program. The company continues to expect to meet all previously disclosed data milestones for the remainder of 2024.
As a result of this announcement, shares of Zentalis Pharmaceuticals have surged by 35% in pre-market trading on Monday.
